Statements (66)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:immunotherapy
|
gptkbp:approves |
gptkb:1998
gptkb:FDA adults |
gptkbp:available_on |
generic drug
|
gptkbp:belongs_to |
non-nucleoside reverse transcriptase inhibitors
|
gptkbp:brand |
gptkb:Atripla
gptkb:Sustiva Symfi Symfi Lo |
gptkbp:can_be_combined_with |
gptkb:tenofovir
gptkb:emtricitabine |
gptkbp:chemical_formula |
C14 H9 Cl F3 NO2
|
gptkbp:class |
arylpropylamine derivatives
|
gptkbp:clinical_trial |
Phase II
Phase III Phase I |
gptkbp:composed_by |
gptkb:chemical_compound
|
gptkbp:contraindication |
pregnancy
certain antidepressants certain anticonvulsants |
gptkbp:developed_by |
gptkb:Bristol-Myers_Squibb
|
gptkbp:dosage_form |
gptkb:tablet
gptkb:capsule oral tablet 600 mg once daily |
gptkbp:drug_interactions |
may decrease levels of certain drugs
may increase levels of certain drugs |
gptkbp:excretion |
urine
feces |
https://www.w3.org/2000/01/rdf-schema#label |
efavirenz
|
gptkbp:interacts_with |
gptkb:St._John's_Wort
gptkb:rifampin CYP450 inducers |
gptkbp:invention |
gptkb:2013
|
gptkbp:is_monitored_by |
liver function tests
lipid levels neuropsychiatric symptoms |
gptkbp:lifespan |
40 to 55 hours
about 40 to 55 hours |
gptkbp:marketed_as |
many countries
|
gptkbp:mechanism_of_action |
non-nucleoside reverse transcriptase inhibitor
non-competitive inhibition of reverse transcriptase |
gptkbp:metabolism |
liver
CYP2 B6 |
gptkbp:provides_guidance_on |
WHO guidelines
CDC guidelines AIDS Clinical Trials Group guidelines often combined with tenofovir and emtricitabine |
gptkbp:research_focus |
long-term effects
combination therapies drug resistance |
gptkbp:route_of_administration |
oral
|
gptkbp:safety |
Category D
|
gptkbp:side_effect |
dizziness
nausea liver toxicity rash insomnia hyperlipidemia neuropsychiatric symptoms |
gptkbp:storage |
room temperature
|
gptkbp:used_for |
treatment of HIV
HIV treatment |
gptkbp:bfsParent |
gptkb:Atripla
|
gptkbp:bfsLayer |
5
|